We previously identified a novel interaction between tuberous sclerosis-2
(TSC2) and death-associated protein kinase-1 (DAPK), the consequence
being that DAPK catalyses the inactivating phosphorylation of TSC2 to
stimulate mammalian target of rapamycin complex 1 (mTORC1) activity.
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:
An unusual case of congenital melanocytic nevus presenting as neurocutaneous melanoma coexisting with Tuberous Sclerosis complex: A case report...
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài:
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors
In tuberous sclerosis, the earliest cutaneous sign is an ash leaf spot. These lesions are often present at birth and are usually multiple; however, detection may require Wood's lamp examination, especially in fair-skinned individuals. The pigment within them is reduced but not absent. The average size is 1–3 cm, and the common shapes are polygonal and lance-ovate.
Papulonodular Skin Lesions (Table 54-15) In the papulonodular diseases, the lesions are elevated above the surface of the skin and may coalesce to form plaques. The location, consistency, and color of the lesions are the keys to their diagnosis; this section is organized on the basis of color.
Table 54-15 Papulonodular Skin Lesions According to Color Groups
A. Calcinosis cutis
A. Rheumatoid nodules
B. Neurofibromas (von Recklinghausen's disease)
C. Angiofibromas (tuberous sclerosis, MEN syndrome, type 1)
D. Neuromas (MEN syndrome, type 2b)
Insulin like growth factor-1 (IGF-1) is established as an anabolic factor
that can induce skeletal muscle growth by activating the phosphoinosi-tide 3-kinase⁄Akt⁄mammalian target of rapamycin (mTOR) pathway.
Although this signaling pathway has been the subject of much study, the
molecular mechanisms linking IGF-1 binding to mTOR activation remain
poorly defined in muscle.